{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:02:17Z","timestamp":1790791337066,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Novartis Pharma Belgium"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40266-025-01265-7","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T02:34:46Z","timestamp":1763692486000},"page":"89-98","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness of Sacubitril\/Valsartan in Reducing Hospitalizations in Older Belgian Adults with Heart Failure and Reduced Ejection Fraction: An Age-Stratified Study"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7517-1988","authenticated-orcid":false,"given":"El\u00e9onore","family":"Maury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5195-1891","authenticated-orcid":false,"given":"Lorenz","family":"Van der Linden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0188-8665","authenticated-orcid":false,"given":"Kris","family":"Bogaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1332-2917","authenticated-orcid":false,"given":"Ann","family":"Belmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2453-7972","authenticated-orcid":false,"given":"Mieke","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"issue":"6","key":"1265_CR1","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1001\/archinternmed.2011.31","volume":"171","author":"A Cherubini","year":"2011","unstructured":"Cherubini A, Oristrell J, Pla X, Ruggiero C, Ferretti R, Diestre G, et al. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med. 2011;171(6):550\u20136.","journal-title":"Arch Intern Med"},{"issue":"8","key":"1265_CR2","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/ejhf.1858","volume":"22","author":"A Groenewegen","year":"2020","unstructured":"Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342\u201356.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"1265_CR3","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/ejhf.483","volume":"18","author":"EE van Riet","year":"2016","unstructured":"van Riet EE, Hoes AW, Wagenaar KP, Limburg A, Landman MA, Rutten FH. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail. 2016;18(3):242\u201352.","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"1265_CR4","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41569-024-01046-6","volume":"21","author":"MS Khan","year":"2024","unstructured":"Khan MS, Shahid I, Bennis A, Rakisheva A, Metra M, Butler J. Global epidemiology of heart failure. Nat Rev Cardiol. 2024;21(10):717\u201334.","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"1265_CR5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jchf.2021.09.004","volume":"10","author":"J Tromp","year":"2022","unstructured":"Tromp J, Ouwerkerk W, van Veldhuisen DJ, Hillege HL, Richards AM, van der Meer P, et al. A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction. JACC Heart Fail. 2022;10(2):73\u201384.","journal-title":"JACC Heart Fail"},{"issue":"11","key":"1265_CR6","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993\u20131004.","journal-title":"N Engl J Med"},{"issue":"36","key":"1265_CR7","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"38","key":"1265_CR8","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1093\/eurheartj\/ehv330","volume":"36","author":"PS Jhund","year":"2015","unstructured":"Jhund PS, Fu M, Bayram E, Chen CH, Negrusz-Kawecka M, Rosenthal A, et al. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J. 2015;36(38):2576\u201384.","journal-title":"Eur Heart J"},{"issue":"7","key":"1265_CR9","first-page":"761","volume":"8","author":"YMF Lim","year":"2022","unstructured":"Lim YMF, Molnar M, Vaartjes I, Savarese G, Eijkemans MJC, Uijl A, et al. Generalizability of randomized controlled trials in heart failure with reduced ejection fraction. Eur Heart J. 2022;8(7):761\u20139.","journal-title":"Eur Heart J"},{"issue":"5","key":"1265_CR10","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1002\/ehf2.13547","volume":"8","author":"S Giovinazzo","year":"2021","unstructured":"Giovinazzo S, Carmisciano L, Toma M, Benenati S, Tomasoni D, Sormani MP, et al. Sacubitril\/valsartan in real-life European patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis. ESC Heart Fail. 2021;8(5):3547\u201356.","journal-title":"ESC Heart Fail."},{"issue":"12","key":"1265_CR11","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.jchf.2022.07.001","volume":"10","author":"SP Murphy","year":"2022","unstructured":"Murphy SP, Ward JH, Pina IL, Felker GM, Butler J, Maisel AS, et al. Age differences in effects of sacubitril\/valsartan on cardiac remodeling, biomarkers, and health status. JACC Heart Fail. 2022;10(12):976\u201388.","journal-title":"JACC Heart Fail"},{"issue":"16","key":"1265_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13164772","volume":"13","author":"LN Roca","year":"2024","unstructured":"Roca LN, Garcia MC, German JB, Becerra AJB, Otero JMR, Chapel JAE, et al. Use and benefit of sacubitril\/valsartan in elderly patients with heart failure with reduced ejection fraction. J Clin Med. 2024;13(16):4772.","journal-title":"J Clin Med"},{"issue":"17","key":"1265_CR13","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1136\/heartjnl-2021-319405","volume":"107","author":"RJ Desai","year":"2021","unstructured":"Desai RJ, Patorno E, Vaduganathan M, Mahesri M, Chin K, Levin R, et al. Effectiveness of angiotensin-neprilysin inhibitor treatment versus renin-angiotensin system blockade in older adults with heart failure in clinical care. Heart. 2021;107(17):1407\u201316.","journal-title":"Heart"},{"issue":"8","key":"1265_CR14","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/ejhf.3417","volume":"27","author":"M Yang","year":"2024","unstructured":"Yang M, Kondo T, Anand IS, de Boer RA, Campbell RT, Kober L, et al. Clinical characteristics and outcomes of patients aged 80 years and over with heart failure: need for better treatment. Eu J Heart Fail. 2024;27(8):1403\u201317.","journal-title":"Eu J Heart Fail."},{"issue":"10","key":"1265_CR15","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1002\/ejhf.3404","volume":"26","author":"D Stolfo","year":"2024","unstructured":"Stolfo D, Benson L, Lindberg F, Dahlstrom U, Kack O, Sinagra G, et al. Status and timing of angiotensin receptor-neprilysin inhibitor implementation in patients with heart failure and reduced ejection fraction: data from the Swedish Heart Failure Registry. Eur J Heart Fail. 2024;26(10):2243\u201357.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"1265_CR16","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1002\/ejhf.3295","volume":"26","author":"G Savarese","year":"2024","unstructured":"Savarese G, Lindberg F, Cannata A, Chioncel O, Stolfo D, Musella F, et al. How to tackle therapeutic inertia in heart failure with reduced ejection fraction: a scientific statement of the Heart Failure Association of the ESC. Eur J Heart Fail. 2024;26(6):1278\u201397.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"1265_CR17","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/bcp.16357","volume":"91","author":"L Van der Linden","year":"2025","unstructured":"Van der Linden L, Tsuyuki R. Between scylla and charybdis: navigating heart failure management in complex older adults. Br J Clin Pharmacol. 2025;91(2):306\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"41","key":"1265_CR18","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1093\/eurheartj\/ehw226","volume":"37","author":"SL Kristensen","year":"2016","unstructured":"Kristensen SL, Martinez F, Jhund PS, Arango JL, Belohlavek J, Boytsov S, et al. Geographic variations in the PARADIGM-HF heart failure trial. Eur Heart J. 2016;37(41):3167\u201374.","journal-title":"Eur Heart J"},{"issue":"18","key":"1265_CR19","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022;145(18):e895-1032.","journal-title":"Circulation"},{"issue":"1","key":"1265_CR20","doi-asserted-by":"publisher","first-page":"13512","DOI":"10.1038\/s41598-024-64243-w","volume":"14","author":"E Maury","year":"2024","unstructured":"Maury E, Belmans A, Bogaerts K, Vancayzeele S, Jansen M. Real-life effectiveness of sacubitril\/valsartan in older Belgians with heart failure, reduced ejection fraction and most severe symptoms. Sci Rep. 2024;14(1):13512.","journal-title":"Sci Rep"},{"issue":"23","key":"1265_CR21","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","volume":"316","author":"Group CTS","year":"1987","unstructured":"Group CTS. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429\u201335.","journal-title":"N Engl J Med"},{"issue":"12","key":"1265_CR22","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1001\/jamacardio.2018.3957","volume":"3","author":"PK Srivastava","year":"2018","unstructured":"Srivastava PK, Claggett BL, Solomon SD, McMurray JJV, Packer M, Zile MR, et al. Estimated 5-year number needed to treat to prevent cardiovascular death or heart failure hospitalization with angiotensin receptor-neprilysin inhibition vs standard therapy for patients with heart failure with reduced ejection fraction: an analysis of data from the PARADIGM-HF trial. JAMA Cardiol. 2018;3(12):1226\u201331.","journal-title":"JAMA Cardiol"},{"key":"1265_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ahj.2022.04.007","volume":"250","author":"L Gilstrap","year":"2022","unstructured":"Gilstrap L, Zipkin RJ, Barnes JA, King A, O\u2019Malley AJ, Gaziano TA, et al. Sacubitril\/valsartan vs ACEi\/ARB at hospital discharge and 5-year survival in older patients with heart failure with reduced ejection fraction: a decision analysis approach. Am Heart J. 2022;250:23\u20138.","journal-title":"Am Heart J"},{"issue":"8","key":"1265_CR24","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s40266-023-01046-0","volume":"40","author":"L Van der Linden","year":"2023","unstructured":"Van der Linden L, Hias J, Walgraeve K, Petrovic M, Tournoy J, Vandenbriele C, et al. Guideline-directed medical therapies for heart failure with a reduced ejection fraction in older adults: a narrative review on efficacy, safety and timeliness. Drugs Aging. 2023;40(8):691\u2013702.","journal-title":"Drugs Aging"},{"issue":"12","key":"1265_CR25","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s40266-022-00987-2","volume":"39","author":"L Van der Linden","year":"2022","unstructured":"Van der Linden L, Hias J, Walgraeve K, Tournoy J, Van Aelst L, Vandenbriele C. Estimating the time to benefit for therapies in heart failure with reduced ejection fraction: a case study of sacubitril-valsartan using reconstructed data from a randomized controlled trial. Drugs Aging. 2022;39(12):959\u201366.","journal-title":"Drugs Aging"},{"issue":"2","key":"1265_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1136\/ejhpharm-2020-002561","volume":"30","author":"L Hellemans","year":"2023","unstructured":"Hellemans L, Mertens B, Hias J, Tournoy J, Van der Linden LR. Age is just a number: the concept of time to benefit in older adults. Eur J Hosp Pharm. 2023;30(2):117\u20139.","journal-title":"Eur J Hosp Pharm"},{"issue":"6","key":"1265_CR27","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/ejhf.2483","volume":"24","author":"D Stolfo","year":"2022","unstructured":"Stolfo D, Lund LH, Becher PM, Orsini N, Thorvaldsen T, Benson L, et al. Use of evidence-based therapy in heart failure with reduced ejection fraction across age strata. Eur J Heart Fail. 2022;24(6):1047\u201362.","journal-title":"Eur J Heart Fail"},{"key":"1265_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2023.131706","volume":"400","author":"X Garcia-Moll","year":"2024","unstructured":"Garcia-Moll X, Lopez L. Safety of sacubitril\/valsartan among older adults: where real world data meet clinical trials results. Int J Cardiol. 2024;400:131706.","journal-title":"Int J Cardiol"},{"key":"1265_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2023.131613","volume":"397","author":"TT Lerman","year":"2024","unstructured":"Lerman TT, Greenberg N, Fishman B, Goldman A, Talmor-Barkan Y, Bauer M, et al. The real-world safety of sacubitril\/valsartan among older adults (\u226575): a pharmacovigilance study from the FDA data. Int J Cardiol. 2024;397:131613.","journal-title":"Int J Cardiol"},{"issue":"10","key":"1265_CR30","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1001\/jamacardio.2024.2181","volume":"9","author":"L Van der Linden","year":"2024","unstructured":"Van der Linden L, Mullens W. Heart failure: together we go farther. JAMA Cardiol. 2024;9(10):947\u20138.","journal-title":"JAMA Cardiol"},{"key":"1265_CR31","unstructured":"Zorgzaam Leuven. https:\/\/www.zorgzaamleuven.be\/. Accessed 1 June 2025."}],"container-title":["Drugs &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01265-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-025-01265-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01265-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T14:27:57Z","timestamp":1769696877000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-025-01265-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1265"],"URL":"https:\/\/doi.org\/10.1007\/s40266-025-01265-7","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"El\u00e9onore Maury and Mieke Jansen are employees of the sponsor. Ann Belmans and Kris Bogaerts were paid by the sponsor via their institution to perform the analyses. Lorenz Van der Linden has no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This secondary analysis of pseudonymized data was conducted in accordance with applicable regulations and approved by the Belgian Data Protection Authority. The need for informed consent was waived under national guidelines. All the protocols including the collection of data complied with the European General Data Protection Regulations. The purpose of this study and data processing were detailed in a privacy notice made available to the healthcare professional community in Belgium, aimed at informing patients treated with sacubitril\/valsartan, per request of the Belgian Data Protection Authority.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Additional information is available from the corresponding author (eleonore.maury@novartis.com) upon reasonable request. The information presented in this paper combines several Belgian administrative databases. The data use is subject to the European Union\u2019s General Data Protection Regulation. Patient-level data were available via the healthdata.be in the framework of a managed entry agreement between Novartis and the payer institute National Institute for Health and Disability Insurance (NIHDI-RIZIV-INAMI). Access to data was restricted to address uncertainties in the context of a managed entry agreement and related publication. Patient-level data may not be shared publicly or transferred because of ethical reasons and security considerations.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Concept: MJ, LV. Conduct: EM, MJ. Interpretation: EM, LV, MJ, AB, KB. Writing: LV and EM drafted the manuscript, reviewed and edited by EM, LV, MJ, AB, KB.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}